Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Feb 4 (Reuters) - Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the ...

A Novo executive noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes ...

Novo Nordisk vowed to take legal action against telehealth company Hims & Hers for selling a knockoff of its weight loss pill ...

Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our ...

Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving ...

Novo Nordisk today announced the launch of a new consumer campaign for Ozempic (R) (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The ...

Novo Nordisk threatens legal action against Hims & Hers for "duping" public with cheap compounds of its popular weight-loss ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.

The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, ...

Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine ...

Novo Nordisk brought in Justin Long and John Hodgman, who had been in the Apple "Get A Mac" ads from 20 years ago, to star in ...